Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02521194
Other study ID # 2015-0350
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date November 13, 2015
Est. completion date January 5, 2020

Study information

Verified date January 2020
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this research study is to learn if inpatient occupational therapy can help patients in the Palliative Care Unit (PCU).


Description:

Caregivers Consent:

If you agree to take part in this study, you will complete a questionnaire about your opinion on the inpatient occupational therapy session the patient (person you are caring for) received. It should take about 10 minutes to complete the questionnaire. You will be left alone in a room to complete the questionnaire.

Length of Study:

Your participation on this study will be over after you complete the questionnaire.

This is an investigational study.

50 patients and up to 50 caregivers will take part in this study. All will be enrolled at MD Anderson.

Patients Consent:

If you agree to take part in this study, you will complete a questionnaire about your opinion of the inpatient occupational therapy session you just had. The questionnaire should take about 10 minutes to complete. You will be left alone in the room to complete the questionnaire.

Length of Study:

You participation on this study will be over after you complete the questionnaire.

This is an investigational study.

50 patients and up to 50 caregivers will take part in this study. All will be enrolled at MD Anderson.


Recruitment information / eligibility

Status Terminated
Enrollment 86
Est. completion date January 5, 2020
Est. primary completion date January 5, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients must have an inpatient occupational therapy (OT) order and be able to tolerate an OT session as judged by the attending physician

2. Patients with cancer admitted to inpatient acute palliative care unit

3. Caregiver participation is optional, but must be identified as the primary caregiver in order to complete the Caregiver Satisfaction Survey.

4. Caregiver (if participating) must be present during the session.

5. Patient (and caregiver (if participating) must be 18 years of age or older.

6. Both patient (and caregiver if participating) must be able to understand, read, write and speak English.

7. Both patient and caregiver (if participating) must sign an Informed Consent Form.

Exclusion Criteria:

1. Patients or caregivers with physical limitations (visual or motor impairment) causing inability to read, complete or sign the consent form and survey.

2. Patients or caregivers who the attending physician deems unable to participate due to poor cognitive capacity or acute physical distress.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Questionnaire
Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.

Locations

Country Name City State
United States University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Satisfaction Rate of Inpatient Occupational Therapy Session Satisfaction rate defined as the percentage of patients that "strongly agree" or "agree" after inpatient occupational session as being beneficial. 1 day
See also
  Status Clinical Trial Phase
Completed NCT01213238 - Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab Phase 1
Recruiting NCT02160366 - Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
Completed NCT00379353 - The Effects of Thalidomide on Symptom Clusters Phase 2
Completed NCT00903708 - LY2275796 in Advanced Cancer Phase 1
Terminated NCT00499382 - Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging N/A
Completed NCT02459964 - Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain Phase 4
Completed NCT01430572 - Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients Phase 1
Completed NCT02561234 - A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT01375114 - The Effects of Ginseng on Cancer-Related Fatigue Phase 2
Completed NCT01201694 - Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) Phase 1
Completed NCT01454804 - Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors Phase 1
Completed NCT02801045 - Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient N/A
Completed NCT02873975 - A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency Phase 2
Completed NCT01983969 - Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Phase 1/Phase 2
Completed NCT02272595 - Rational Therapeutics Based on Matched Tumor and Normal Tissue
Active, not recruiting NCT01999491 - A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma Phase 1
Recruiting NCT03375983 - Plasmodium Immunotherapy for Advanced Cancers Phase 1/Phase 2
Completed NCT02571036 - A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Phase 1
Withdrawn NCT01608139 - Study of Curcumin, Vorinostat, and Sorafenib Phase 1
Completed NCT01024166 - Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study N/A